combined analyses of pd-l1 and tils for therapy selection in tnbc
Published 3 years ago • 202 plays • Length 1:38Download video MP4
Download video MP3
Similar videos
-
4:22
neotripapdl1: dynamics of tils & pd-l1 expression in breast cancer
-
4:27
analysis of impassion130: pd-l1 testing in advanced tnbc
-
7:09
personalizing immunotherapy beyond pdl1 expression
-
4:05
analysis and comparison of pd-l1 ihc tests
-
2:05
treatment advances in tnbc
-
1:15
clinical implications of progress in tnbc therapies
-
6:56
impassion130 trial data on pd-l1 tumors in tnbc
-
4:46
performance of pd-l1 ihc assays in impassion130: a post-hoc analysis
-
1:24
combining chemotherapy, cd40 agonist, and flt3 ligand in triple-negative breast cancer
-
1:03
new directions in immunotherapy for improving outcomes in tnbc
-
2:16
tailoring neoadjuvant and adjuvant therapy in tnbc
-
4:38
alice: atezolizumab immunogenic chemotherapy in metastatic tnbc
-
3:37
case 3: pd-l1 testing used in triple-negative breast cancer
-
3:37
problems with pd-l1 expression testing in patients with nsclc
-
2:46
de-escalation of therapy in early-stage tnbc
-
1:45
combined blockade of vegf and pd-1 signaling in rcc
-
4:32
pd-1 and ox40: potential pdac combination therapy
-
4:40
case 3: the use of combination therapy in triple-negative breast cancer
-
2:01
tumor infiltrating lymphocytes (tils) as a predictive biomarker in breast cancer